Letter abstract
Nature Genetics 41, 1122 - 1126 (2009)
Published online: 20 September 2009 | doi:10.1038/ng.448
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility
Julius Gudmundsson1,21, Patrick Sulem1,21, Daniel F Gudbjartsson1, Thorarinn Blondal1, Arnaldur Gylfason1, Bjarni A Agnarsson2,3, Kristrun R Benediktsdottir2,3, Droplaug N Magnusdottir1, Gudbjorg Orlygsdottir1, Margret Jakobsdottir1, Simon N Stacey1, Asgeir Sigurdsson1, Tiina Wahlfors4, Teuvo Tammela5, Joan P Breyer6, Kate M McReynolds6, Kevin M Bradley6, Berta Saez7,8, Javier Godino7, Sebastian Navarrete9, Fernando Fuertes9, Laura Murillo10, Eduardo Polo11, Katja K Aben12,13, Inge M van Oort14, Brian K Suarez15, Brian T Helfand16, Donghui Kan16, Carlo Zanon1,17, Michael L Frigge1, Kristleifur Kristjansson1, Jeffrey R Gulcher1, Gudmundur V Einarsson18, Eirikur Jonsson18, William J Catalona16, Jose I Mayordomo7,8,19, Lambertus A Kiemeney12,14, Jeffrey R Smith6,20, Johanna Schleutker4, Rosa B Barkardottir2, Augustine Kong1, Unnur Thorsteinsdottir1,3, Thorunn Rafnar1 & Kari Stefansson1,3
Abstract
We report a prostate cancer genome-wide association follow-on study. We discovered four variants associated with susceptibility to prostate cancer in several European populations: rs10934853[A] (OR = 1.12, P = 2.9 
10-10) on 3q21.3; two moderately correlated (r2 = 0.07) variants, rs16902094[G] (OR = 1.21, P = 6.2 10-15) and rs445114[T] (OR = 1.14, P = 4.7 10-10), on 8q24.21; and rs8102476[C] (OR = 1.12, P = 1.6 10-11) on 19q13.2. We also refined a previous association signal on 11q13 with the SNP rs11228565[A] (OR = 1.23, P = 6.7 10-12). In a multivariate analysis using 22 prostate cancer risk variants typed in the Icelandic population, we estimated that carriers in the top 1.3% of the risk distribution are at a 2.5 times greater risk of developing the disease than members of the general population.
- deCODE Genetics, Reykjavik, Iceland.
- Department of Pathology, Landspitali–University Hospital, Reykjavik, Iceland.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.
- Department of Urology, Tampere University Hospital, University of Tampere, Tampere, Finland.
- Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- Health Science Institute of Aragon, Zaragoza, Spain.
- Nanotechnology Institute of Aragon, Zaragoza, Spain.
- Division of Radiation Oncology, Lozano Blesa University Hospital, University of Zaragoza, Zaragoza, Spain.
- Division of Medical Oncology, Reina Sofia Hospital, Tudela, Spain.
- Division of Medical Oncology, Ernest Lluch Hospital, Calatayud, Spain.
- Comprehensive Cancer Center East, Nijmegen, The Netherlands.
- Department of Epidemiology, Biostatistics & Health Technology Assessment Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
- Department of Urology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy.
- Department of Urology, Landspitali–University Hospital, Reykjavik, Iceland.
- Division of Medical Oncology, University Hospital, University of Zaragoza, Zaragoza, Spain.
- Medical Research Service, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA.
- These authors contributed equally to this work.
Correspondence to: Kari Stefansson1,3 e-mail: kstefans@decode.is
Correspondence to: Javier Godino7 e-mail: julius@decode.is.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancerNature Genetics Brief Communication (01 Mar 2008)
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetesNature Genetics Letter (01 Aug 2007)
Sequence variant on 8q24 confers susceptibility to urinary bladder cancerNature Genetics Letter (01 Nov 2008)
See all 52 matches for Research
